Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 10, 2007, Pages 3803-3808

  Silverberg, Shonni J ^a   Rubin, M R ^a   Faiman, C ^b   Peacock, M ^c   Shoback, D M ^d   Smallridge, R C ^e   Schwanauer, L E ^f   Olson, K A ^f   Klassen, P ^f   Bilezikian, J P ^a  

^a Columbia University ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MAYO CLINIC   (United States)

^f AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRACTURE; HUMAN; HYPERCALCEMIA; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARATHYROID CARCINOMA; PARATHYROID GLAND; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URTICARIA; VOMITING;

EID: 35349007445     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0585     Document Type: Article

References (30)

1. Cordeiro AC, Montenegro FL, Kulcsar MA, Dellanegra LA, Tavares MR, Michaluart Jr P, Ferraz AR 1998 Parathyroid carcinoma. Am J Surg 175:52-55
2. Fraker DL 2000 Update on the management of parathyroid tumors. Curr Opin Oncol 12:41-48
3. Shane E 2001 Parathyroid carcinoma. J Clin Endocrinol Metab 86:485-493
4. Kebebew E, Arici C, Duh QY, Clark OH 2001 Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 136:878-885
5. Wang CA, Gaz RD 1985 Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg 149:522-527
6. Stock JL, Marcus R 2001 Medical management of primary hyperparathyroidism in the United States. In: Bilezikian JP, ed. The parathyroids. San Diego: Academic Press; 459-474
7. Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, Ghaye B, Daly AF, Beckers A 2004 Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 89:3413-3420
8. Shoback DM, Arends RH, Roskos L, Shetty S, Wyres M, Huang S, Raie N, Bell GM 2004 Treatment of parathyroid carcinoma with ABX10241, a monoclonal antibody to parathyroid hormone. J Bone Miner Res 17(Suppl 1):SA498 (Abstract)
9. Schott M, Feldkamp J, Schattenberg D, Krueger T, Dotzenrath C, Seissler J, Scherbaum WA 2000 Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 142:300-306
10. 2+-sensing receptor from bovine parathyroid. Nature 366:575-580
11. Nemeth EF, Steffey ME, Hammerland LG, Hung BCP, Van Wagenen BC, Delmar EG, Balandrin MF 1998 Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040-4045
12. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ 1998 Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083-1088
13. Peacock M, Bilezikian JP, Scumpia S, Bolognese MA, Borofsky MA, Turner SA, Guo MD, McCary LC, Shoback DM 2004 Cinacalcet HCl is an effective therapy for the hypercalcemia of primary hyperparathyroidism across a broad range of patients. J Bone Miner Res 17(Suppl 1):1199 (Abstract)
14. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D 2005 Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135-141
15. Stewart A, Ware Jr JE 1998 Measuring functioning and well being: the medical outcomes study approach. Durham, NC: Duke University Press
16. Ware Jr JE 1997 SF-36 Health survey: manual and interpretation guide. Health Inst 7:1-7
17. Au WY 1975 Calcitonin treatment of hypercalcemia due to parathyroid carcinoma: synergistic effect of prednisone on long-term treatment of hypercalcemia. Arch Int Med 135:1594
18. Newrick PG, Braatvedt GD, Webb AJ, Sheffield E, Corrall RJM 1994 Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. Postgrad Med J 70:231-232
19. Mann K 1985 Oral biphosphonate therapy in metastatic parathyroid carcinoma. Lancet 1:101-102
20. Jungst D 1984 Disodium clodronate effective in management of severe hypercalcaemia caused by parathyroid carcinoma. Lancet 2:1043
21. Levi R, Ben-Dov IZ, Lavi-Moshayoff V, Dinur M, Martin D, Naveh-Many T, Silver J 2006 Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol 7:107-112
22. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D 2004 Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627-635
23. Padhi D, Harris RZ, Salfi M, Sullivan, JT 2005 No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara). Clin Pharmacokinet 44:509-516
24. Harris RZ, Padhi D, Marbury TC, Noveck RJ, Salfi M, Sullivan JT 2004 Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 44:1070-1076
25. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D 2005 Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67:467-476
26. Davis J, Miller J, Shatzen E, Henley C, Martin D 2005 Cinacalcet HCl increases expression of p21 in the parathyroid and reversibly inhibits parathyroid hyperplasia in a rodent model of CKD. Nephrol Dial Transplant 20(Suppl 5):v204 (Abstract)
27. Block GA, Martin KJ, de Francisco AL, Turner SA,. Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG 2004 Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525
28. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V 2005 Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46:58-67
29. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen, PS, Guo MD, Albizem MB, Coburn JW 2005 Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16:800-807
30. Shoback DM, Bilzekian JP, Turner SA, McCary LC, Guo MD, Peacock M 2003 The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88:5644-5649